Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 50% · prior close shown (market closed)
Limited proprietary earnings coverage for AVBP yet — signals will sharpen as filings and earnings are ingested.
Pipeline evidence · 0d ago
AVBP's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on AVBP.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for ArriVent BioPharma, Inc. (AVBP) — events, not interpretation.
Research & analysis only — not investment advice.
Held in ETFsweight · est. sleeve dollars
AlphaOS industries
Investment snapshot
AVBP's AI investment thesis
Upgrade to Premium for AVBP's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$28.45
Market cap
$1.40B
Profitable
No
Net income
$-166.31M
FY Dec 31, 2025
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for ArriVent BioPharma, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow ArriVent BioPharma, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.